CUMYL-PINACA: Difference between revisions
CSV import |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Synthetic cannabinoid}} | |||
{{Drugbox | {{Drugbox | ||
| verifiedrevid = 477318464 | | verifiedrevid = 477318464 | ||
| IUPAC_name = 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide | | IUPAC_name = 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide | ||
| image = CUMYL- | | image = CUMYL-PINACA.png | ||
| width = 200 | | width = 200 | ||
| legal_CA = Schedule II | | legal_CA = Schedule II | ||
| Line 20: | Line 20: | ||
| StdInChIKey = QXKJXQKZBIBTDI-UHFFFAOYSA-N | | StdInChIKey = QXKJXQKZBIBTDI-UHFFFAOYSA-N | ||
}} | }} | ||
'''CUMYL-PINACA''' is a [[synthetic cannabinoid]] that has been used as an active ingredient in [[synthetic cannabis]] products. It is a potent [[agonist]] of the [[CB1 receptor]] and [[CB2 receptor]], which are part of the [[endocannabinoid system]]. | '''CUMYL-PINACA''' is a [[synthetic cannabinoid]] that has been used as an active ingredient in [[synthetic cannabis]] products. It is a potent [[agonist]] of the [[CB1 receptor]] and [[CB2 receptor]], which are part of the [[endocannabinoid system]]. | ||
| Line 41: | Line 40: | ||
* [[CB2 receptor]] | * [[CB2 receptor]] | ||
* [[Tetrahydrocannabinol]] | * [[Tetrahydrocannabinol]] | ||
[[Category:Synthetic cannabinoids]] | [[Category:Synthetic cannabinoids]] | ||
[[Category:Indazolecarboxamides]] | [[Category:Indazolecarboxamides]] | ||
| Line 50: | Line 45: | ||
[[Category:CB1 receptor agonists]] | [[Category:CB1 receptor agonists]] | ||
[[Category:CB2 receptor agonists]] | [[Category:CB2 receptor agonists]] | ||
{{Drug-stub}} | {{Drug-stub}} | ||
<gallery> | |||
File:CUMYL-PINACA.png|CUMYL-PINACA | |||
</gallery> | |||
Latest revision as of 00:56, 20 February 2025
Synthetic cannabinoid
| CUMYL-PINACA | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 1400742-14-7 |
| PubChem | 118796952 |
| DrugBank | |
| ChemSpider | 29762284 |
| KEGG | |
CUMYL-PINACA is a synthetic cannabinoid that has been used as an active ingredient in synthetic cannabis products. It is a potent agonist of the CB1 receptor and CB2 receptor, which are part of the endocannabinoid system.
Chemical Structure and Properties[edit]
CUMYL-PINACA is chemically classified as an indazole-based synthetic cannabinoid. Its full chemical name is 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide. The compound has a molecular formula of C22H25N3O and a molecular weight of 347.46 g/mol.
Pharmacology[edit]
CUMYL-PINACA acts as a potent agonist at the CB1 receptor and CB2 receptor, which are part of the endocannabinoid system. These receptors are involved in a variety of physiological processes including pain sensation, appetite, and mood. The activation of these receptors by CUMYL-PINACA can lead to effects similar to those produced by tetrahydrocannabinol (THC), the primary psychoactive component of cannabis.
Legal Status[edit]
CUMYL-PINACA is classified as a Schedule I substance under the Controlled Substances Act in the United States, indicating that it is considered to have a high potential for abuse and no accepted medical use. In the United Kingdom, it is classified as a Class B drug under the Misuse of Drugs Act 1971. In Canada, it is listed under Schedule II of the Controlled Drugs and Substances Act.
Health Risks and Toxicity[edit]
The use of synthetic cannabinoids like CUMYL-PINACA has been associated with a range of adverse health effects, including tachycardia, hypertension, nausea, vomiting, hallucinations, and seizures. Due to its potency and the variability in the composition of synthetic cannabis products, the risk of overdose and severe toxicity is significant.
See Also[edit]
-
CUMYL-PINACA
